Survival and comorbidities in lung cancer patients: evidence from administrative claims data in Germany

Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still debated. We analyzed administrative claims data from one of the largest...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hernández, Diego (VerfasserIn) , Cheng, Chih-Yuan (VerfasserIn) , Hernandez-Villafuerte, Karla (VerfasserIn) , Schlander, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 31 January 2023
In: Oncology research
Year: 2023, Jahrgang: 30, Heft: 4, Pages: 173-185
ISSN:1555-3906
DOI:10.32604/or.2022.027262
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.32604/or.2022.027262
Verlag, lizenzpflichtig, Volltext: https://www.techscience.com/or/v30n4/51395
Volltext
Verfasserangaben:Diego Hernandez, Chih-Yuan Cheng, Karla Hernandez-Villafuerte, Michael Schlander

MARC

LEADER 00000caa a2200000 c 4500
001 1842855786
003 DE-627
005 20230706213117.0
007 cr uuu---uuuuu
008 230417s2023 xx |||||o 00| ||eng c
024 7 |a 10.32604/or.2022.027262  |2 doi 
035 |a (DE-627)1842855786 
035 |a (DE-599)KXP1842855786 
035 |a (OCoLC)1389530546 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hernández, Diego  |d 1980-  |e VerfasserIn  |0 (DE-588)1016396708  |0 (DE-627)670385298  |0 (DE-576)352130490  |4 aut 
245 1 0 |a Survival and comorbidities in lung cancer patients  |b evidence from administrative claims data in Germany  |c Diego Hernandez, Chih-Yuan Cheng, Karla Hernandez-Villafuerte, Michael Schlander 
264 1 |c 31 January 2023 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 17.04.2023 
520 |a Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still debated. We analyzed administrative claims data from one of the largest statutory health insurance (SHI) funds in Germany, covering close to 9 million people (11% of the national population); observation period was from 2005 to 2019. Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes. Comorbidities were classified according to the Charlson Comorbidity Index (CCI). Incidence, comorbidity prevalence and survival are estimated considering sex, age at diagnosis, and place of residence. Kaplan Meier curves with 95% confidence intervals were built in relation to common comorbidities. We identified 70,698 lung cancer incident cases in the sample. Incidence and survival figures are comparable to official statistics in Germany. Most prevalent comorbidities are chronic obstructive pulmonary disease (COPD) (36.7%), followed by peripheral vascular disease (PVD) (18.7%), diabetes without chronic complications (17.4%), congestive heart failure (CHF) (16.5%) and renal disease (14.7%). Relative to overall survival, lung cancer patients with CHF, cerebrovascular disease (CEVD) and renal disease are associated with largest drops in survival probabilities (9% or higher), while those with PVD and diabetes without chronic complications with moderate drops (7% or lower). The study showed a negative association between survival and most common comorbidities among lung cancer patients, based on a large sample for Germany. Further research needs to explore the individual effect of comorbidities disentangled from that of other patient characteristics such as cancer stage and histology. 
700 1 |a Cheng, Chih-Yuan  |d 1987-  |e VerfasserIn  |0 (DE-588)1196560838  |0 (DE-627)1678199885  |4 aut 
700 1 |a Hernandez-Villafuerte, Karla  |e VerfasserIn  |4 aut 
700 1 |a Schlander, Michael  |d 1959-  |e VerfasserIn  |0 (DE-588)1036904652  |0 (DE-627)751411957  |0 (DE-576)389587710  |4 aut 
773 0 8 |i Enthalten in  |t Oncology research  |d New York, NY : Cognizant Communication Corporation, 1999  |g 30(2023), 4, Seite 173-185  |h Online-Ressource  |w (DE-627)327962526  |w (DE-600)2044620-2  |w (DE-576)470546182  |x 1555-3906  |7 nnas  |a Survival and comorbidities in lung cancer patients evidence from administrative claims data in Germany 
773 1 8 |g volume:30  |g year:2023  |g number:4  |g pages:173-185  |g extent:13  |a Survival and comorbidities in lung cancer patients evidence from administrative claims data in Germany 
856 4 0 |u https://doi.org/10.32604/or.2022.027262  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.techscience.com/or/v30n4/51395  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230417 
993 |a Article 
994 |a 2023 
998 |g 1036904652  |a Schlander, Michael  |m 1036904652:Schlander, Michael  |p 4  |y j 
998 |g 1196560838  |a Cheng, Chih-Yuan  |m 1196560838:Cheng, Chih-Yuan  |d 60000  |e 60000PC1196560838  |k 0/60000/  |p 2 
998 |g 1016396708  |a Hernández, Diego  |m 1016396708:Hernández, Diego  |p 1  |x j 
999 |a KXP-PPN1842855786  |e 4309354270 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"physDesc":[{"extent":"13 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Hernández, Diego","role":"aut","given":"Diego","family":"Hernández"},{"role":"aut","given":"Chih-Yuan","family":"Cheng","display":"Cheng, Chih-Yuan"},{"family":"Hernandez-Villafuerte","role":"aut","given":"Karla","display":"Hernandez-Villafuerte, Karla"},{"given":"Michael","role":"aut","family":"Schlander","display":"Schlander, Michael"}],"title":[{"title":"Survival and comorbidities in lung cancer patients","subtitle":"evidence from administrative claims data in Germany","title_sort":"Survival and comorbidities in lung cancer patients"}],"name":{"displayForm":["Diego Hernandez, Chih-Yuan Cheng, Karla Hernandez-Villafuerte, Michael Schlander"]},"recId":"1842855786","id":{"doi":["10.32604/or.2022.027262"],"eki":["1842855786"]},"origin":[{"dateIssuedDisp":"31 January 2023","dateIssuedKey":"2023"}],"note":["Gesehen am 17.04.2023"],"relHost":[{"id":{"zdb":["2044620-2"],"issn":["1555-3906"],"eki":["327962526"]},"origin":[{"publisherPlace":"New York, NY ; Amsterdam [u.a.]","dateIssuedKey":"1999","publisher":"Cognizant Communication Corporation ; Elsevier Science","dateIssuedDisp":"1999-"}],"part":{"year":"2023","issue":"4","text":"30(2023), 4, Seite 173-185","extent":"13","pages":"173-185","volume":"30"},"recId":"327962526","disp":"Survival and comorbidities in lung cancer patients evidence from administrative claims data in GermanyOncology research","title":[{"title":"Oncology research","title_sort":"Oncology research"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 21.03.2022"],"pubHistory":["11.1999 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}]}]} 
SRT |a HERNANDEZDSURVIVALAN3120